<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25640182</PMID><DateCompleted><Year>2016</Year><Month>01</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Feb</Month><Day>03</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein.</ArticleTitle><Pagination><StartPage>600</StartPage><EndPage>615</EndPage><MedlinePgn>600-15</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2014.12.054</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(14)01121-8</ELocationID><Abstract><AbstractText>Itraconazole (ITZ) is a well-known antifungal agent that also has anticancer activity. In this study, we identify ITZ as a broad-spectrum inhibitor of enteroviruses (e.g., poliovirus, coxsackievirus, enterovirus-71, rhinovirus). We demonstrate that ITZ inhibits viral RNA replication by targeting oxysterol-binding protein (OSBP) and OSBP-related protein 4 (ORP4). Consistently, OSW-1, a specific OSBP/ORP4 antagonist, also inhibits enterovirus replication. Knockdown of OSBP inhibits virus replication, whereas overexpression of OSBP or ORP4 counteracts the antiviral effects of ITZ and OSW-1. ITZ binds OSBP and inhibits its function, i.e., shuttling of cholesterol and phosphatidylinositol-4-phosphate between membranes, thereby likely perturbing the virus-induced membrane alterations essential for viral replication organelle formation. ITZ also inhibits hepatitis C virus replication, which also relies on OSBP. Together, these data implicate OSBP/ORP4 as molecular targets of ITZ and point to an essential role of OSBP/ORP4-mediated lipid exchange in virus replication that can be targeted by antiviral drugs.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Strating</LastName><ForeName>Jeroen R P M</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Virology Division, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, 3584CL Utrecht, the Netherlands; Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, 6525GA Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Linden</LastName><ForeName>Lonneke</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, 6525GA Nijmegen, the Netherlands; Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, University of Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albulescu</LastName><ForeName>Lucian</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Virology Division, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, 3584CL Utrecht, the Netherlands; Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, 6525GA Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bigay</LastName><ForeName>Jo&#xeb;lle</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institut de Pharmacologie Mol&#xe9;culaire et Cellulaire, Universit&#xe9; Nice Sophia Antipolis and CNRS, UMR 7275, 06560 Valbonne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arita</LastName><ForeName>Minetaro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Virology II, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delang</LastName><ForeName>Leen</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, University of Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leyssen</LastName><ForeName>Pieter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, University of Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Schaar</LastName><ForeName>Hilde M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Virology Division, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, 3584CL Utrecht, the Netherlands; Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, 6525GA Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanke</LastName><ForeName>Kjerstin H W</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, 6525GA Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thibaut</LastName><ForeName>Hendrik Jan</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Virology Division, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, 3584CL Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulferts</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Virology Division, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, 3584CL Utrecht, the Netherlands; Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, 6525GA Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drin</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institut de Pharmacologie Mol&#xe9;culaire et Cellulaire, Universit&#xe9; Nice Sophia Antipolis and CNRS, UMR 7275, 06560 Valbonne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlinck</LastName><ForeName>Nina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>NanoTemper Technologies GmbH, 81369 M&#xfc;nchen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wubbolts</LastName><ForeName>Richard W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, 3584CM Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sever</LastName><ForeName>Navdar</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Developmental Biology, Institute for Stem Cell Biology and Regenerative Medicine, Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Head</LastName><ForeName>Sarah A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jun O</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beachy</LastName><ForeName>Philip A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Developmental Biology, Institute for Stem Cell Biology and Regenerative Medicine, Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Matteis</LastName><ForeName>Maria A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Telethon Institute of Genetics and Medicine, Naples 80131, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shair</LastName><ForeName>Matthew D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olkkonen</LastName><ForeName>Vesa M</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Minerva Foundation Institute for Medical Research, 00290 Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neyts</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, University of Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Kuppeveld</LastName><ForeName>Frank J M</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Virology Division, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, 3584CL Utrecht, the Netherlands; Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, 6525GA Nijmegen, the Netherlands. Electronic address: f.j.m.vankuppeveld@uu.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>HHMI_</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM102498</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>TGM11CB1</GrantID><Acronym>TI_</Acronym><Agency>Telethon</Agency><Country>Italy</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>01</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011987">Receptors, Steroid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054899">oxysterol binding protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>304NUG5GF4</RegistryNumber><NameOfSubstance UI="D017964">Itraconazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017964" MajorTopicYN="N">Itraconazole</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011987" MajorTopicYN="N">Receptors, Steroid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>1</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25640182</ArticleId><ArticleId IdType="mid">NIHMS661351</ArticleId><ArticleId IdType="pmc">PMC4383725</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2014.12.054</ArticleId><ArticleId IdType="pii">S2211-1247(14)01121-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Antonarakis E.S., Heath E.I., Smith D.C., Rathkopf D., Blackford A.L., Danila D.C., King S., Frost A., Ajiboye A.S., Zhao M., et al. Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. Oncologist. 2013;18:163&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3579600</ArticleId><ArticleId IdType="pubmed">23340005</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M. Phosphatidylinositol-4 kinase III beta and oxysterol-binding protein accumulate unesterified cholesterol on poliovirus-induced membrane structure. Microbiol. Immunol. 2014;58:239&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">24527995</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Wakita T., Shimizu H. Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in viral protein 3A similar to that of enviroxime. J.&#xa0;Gen. Virol. 2009;90:1869&#x2013;1879.</Citation><ArticleIdList><ArticleId IdType="pubmed">19439558</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Takebe Y., Wakita T., Shimizu H. A bifunctional anti-enterovirus compound that inhibits replication and the early stage of enterovirus 71 infection. J.&#xa0;Gen. Virol. 2010;91:2734&#x2013;2744.</Citation><ArticleIdList><ArticleId IdType="pubmed">20660150</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Kojima H., Nagano T., Okabe T., Wakita T., Shimizu H. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J.&#xa0;Virol. 2011;85:2364&#x2013;2372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3067798</ArticleId><ArticleId IdType="pubmed">21177810</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Kojima H., Nagano T., Okabe T., Wakita T., Shimizu H. Oxysterol-binding protein family I is the target of minor enviroxime-like compounds. J.&#xa0;Virol. 2013;87:4252&#x2013;4260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624399</ArticleId><ArticleId IdType="pubmed">23365445</ArticleId></ArticleIdList></Reference><Reference><Citation>Balla A., Tuymetova G., Tsiomenko A., V&#xe1;rnai P., Balla T. A plasma membrane pool of phosphatidylinositol 4-phosphate is generated by phosphatidylinositol 4-kinase type-III alpha: studies with the PH domains of the oxysterol binding protein and FAPP1. Mol. Biol. Cell. 2005;16:1282&#x2013;1295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC551492</ArticleId><ArticleId IdType="pubmed">15635101</ArticleId></ArticleIdList></Reference><Reference><Citation>Belov G.A., Nair V., Hansen B.T., Hoyt F.H., Fischer E.R., Ehrenfeld E. Complex dynamic development of poliovirus membranous replication complexes. J.&#xa0;Virol. 2012;86:302&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3255921</ArticleId><ArticleId IdType="pubmed">22072780</ArticleId></ArticleIdList></Reference><Reference><Citation>Beretta L., Svitkin Y.V., Sonenberg N. Rapamycin stimulates viral protein synthesis and augments the shutoff of host protein synthesis upon picornavirus infection. J.&#xa0;Virol. 1996;70:8993&#x2013;8996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC190998</ArticleId><ArticleId IdType="pubmed">8971030</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgett A.W., Poulsen T.B., Wangkanont K., Anderson D.R., Kikuchi C., Shimada K., Okubo S., Fortner K.C., Mimaki Y., Kuroda M., et al. Natural products reveal cancer cell dependence on oxysterol-binding proteins. Nat. Chem. Biol. 2011;7:639&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3158287</ArticleId><ArticleId IdType="pubmed">21822274</ArticleId></ArticleIdList></Reference><Reference><Citation>Charman M., Colbourne T.R., Pietrangelo A., Kreplak L., Ridgway N.D. Oxysterol-binding protein (OSBP)-related protein 4 (ORP4) is essential for cell proliferation and survival. J.&#xa0;Biol. Chem. 2014;289:15705&#x2013;15717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4140924</ArticleId><ArticleId IdType="pubmed">24742681</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J.K., Taipale J., Young K.E., Maiti T., Beachy P.A. Small molecule modulation of Smoothened activity. Proc. Natl. Acad. Sci. USA. 2002;99:14071&#x2013;14076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC137838</ArticleId><ArticleId IdType="pubmed">12391318</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng F., Liu C., Jiang J., Lu W., Li W., Liu G., Zhou W., Huang J., Tang Y. Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput. Biol. 2012;8:e1002503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3349722</ArticleId><ArticleId IdType="pubmed">22589709</ArticleId></ArticleIdList></Reference><Reference><Citation>Doedens J.R., Giddings T.H., Jr., Kirkegaard K. Inhibition of endoplasmic reticulum-to-Golgi traffic by poliovirus protein 3A: genetic and ultrastructural analysis. J.&#xa0;Virol. 1997;71:9054&#x2013;9064.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC230206</ArticleId><ArticleId IdType="pubmed">9371562</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu N.-Y., Ilnytska O., Belov G., Santiana M., Chen Y.-H., Takvorian P.M., Pau C., van der Schaar H., Kaushik-Basu N., Balla T., et al. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell. 2010;141:799&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2982146</ArticleId><ArticleId IdType="pubmed">20510927</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilnytska O., Santiana M., Hsu N.Y., Du W.L., Chen Y.H., Viktorova E.G., Belov G., Brinker A., Storch J., Moore C., et al. Enteroviruses harness the cellular endocytic machinery to remodel the host cell cholesterol landscape for effective viral replication. Cell Host Microbe. 2013;14:281&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3802520</ArticleId><ArticleId IdType="pubmed">24034614</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Tang J.Y., Gong R., Kim J., Lee J.J., Clemons K.V., Chong C.R., Chang K.S., Fereshteh M., Gardner D., et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17:388&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4039177</ArticleId><ArticleId IdType="pubmed">20385363</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D.J., Kim J., Spaunhurst K., Montoya J., Khodosh R., Chandra K., Fu T., Gilliam A., Molgo M., Beachy P.A., Tang J.Y. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J.&#xa0;Clin. Oncol. 2014;32:745&#x2013;751.</Citation><ArticleIdList><ArticleId IdType="pubmed">24493717</ArticleId></ArticleIdList></Reference><Reference><Citation>Lestner J., Hope W.W. Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections. Expert Opin. Drug Metab. Toxicol. 2013;9:911&#x2013;926.</Citation><ArticleIdList><ArticleId IdType="pubmed">23641752</ArticleId></ArticleIdList></Reference><Reference><Citation>Limpens R.W.A.L., Van der Schaar H.M., Kumar D., Koster A.J., Snijder E.J., Van Kuppeveld F.J.M., B&#xe1;rcena M. The transformation of enterovirus replication structures: a three-dimensional study of single- and double-membrane compartments. MBio. 2011;2 e00166-11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3187575</ArticleId><ArticleId IdType="pubmed">21972238</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLeod A.M., Mitchell D.R., Palmer N.J., Van de Po&#xeb;l H., Conrath K., Andrews M., Leyssen P., Neyts J. Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. ACS Med. Chem. Lett. 2013;4:585&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4030314</ArticleId><ArticleId IdType="pubmed">24900715</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesmin B., Bigay J., Moser von Filseck J., Lacas-Gervais S., Drin G., Antonny B. A four-step cycle driven by PI(4)P hydrolysis directs sterol/PI(4)P exchange by the ER-Golgi tether OSBP. Cell. 2013;155:830&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pubmed">24209621</ArticleId></ArticleIdList></Reference><Reference><Citation>Nacev B.A., Grassi P., Dell A., Haslam S.M., Liu J.O. The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells. J.&#xa0;Biol. Chem. 2011;286:44045&#x2013;44056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3243534</ArticleId><ArticleId IdType="pubmed">22025615</ArticleId></ArticleIdList></Reference><Reference><Citation>Peretti D., Dahan N., Shimoni E., Hirschberg K., Lev S. Coordinated lipid transfer between the endoplasmic reticulum and the Golgi complex requires the VAP proteins and is essential for Golgi-mediated transport. Mol. Biol. Cell. 2008;19:3871&#x2013;3884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2526681</ArticleId><ArticleId IdType="pubmed">18614794</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry R.J., Ridgway N.D. Oxysterol-binding protein and vesicle-associated membrane protein-associated protein are required for sterol-dependent activation of the ceramide transport protein. Mol. Biol. Cell. 2006;17:2604&#x2013;2616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1474796</ArticleId><ArticleId IdType="pubmed">16571669</ArticleId></ArticleIdList></Reference><Reference><Citation>Raychaudhuri S., Prinz W.A. The diverse functions of oxysterol-binding proteins. Annu. Rev. Cell Dev. Biol. 2010;26:157&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3478074</ArticleId><ArticleId IdType="pubmed">19575662</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothwell C., Lebreton A., Young Ng C., Lim J.Y., Liu W., Vasudevan S., Labow M., Gu F., Gaither L.A. Cholesterol biosynthesis modulation regulates dengue viral replication. Virology. 2009;389:8&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">19419745</ArticleId></ArticleIdList></Reference><Reference><Citation>Roulin P.S., L&#xf6;tzerich M., Torta F., Tanner L.B., van Kuppeveld F.J., Wenk M.R., Greber U.F. Rhinovirus uses a phosphatidylinositol 4-phosphate/cholesterol counter-current for the formation of replication compartments at the ER-Golgi interface. Cell Host Microbe. 2014;16:677&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pubmed">25525797</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudin C.M., Brahmer J.R., Juergens R.A., Hann C.L., Ettinger D.S., Sebree R., Smith R., Aftab B.T., Huang P., Liu J.O. Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer. J.&#xa0;Thorac. Oncol. 2013;8:619&#x2013;623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3636564</ArticleId><ArticleId IdType="pubmed">23546045</ArticleId></ArticleIdList></Reference><Reference><Citation>Taipale J., Chen J.K., Cooper M.K., Wang B., Mann R.K., Milenkovic L., Scott M.P., Beachy P.A. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature. 2000;406:1005&#x2013;1009.</Citation><ArticleIdList><ArticleId IdType="pubmed">10984056</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Schaar H.M., van der Linden L., Lanke K.H., Strating J.R., P&#xfc;rstinger G., de Vries E., de Haan C.A., Neyts J., van Kuppeveld F.J. Coxsackievirus mutants that can bypass host factor PI4KIII&#x3b2; and the need for high levels of PI4P lipids for replication. Cell Res. 2012;22:1576&#x2013;1592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3494396</ArticleId><ArticleId IdType="pubmed">22945356</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Schaar H.M., Leyssen P., Thibaut H.J., de Palma A., van der Linden L., Lanke K.H., Lacroix C., Verbeken E., Conrath K., Macleod A.M., et al. A novel, broad-spectrum inhibitor of enterovirus replication that targets host cell factor phosphatidylinositol 4-kinase III&#x3b2;. Antimicrob. Agents Chemother. 2013;57:4971&#x2013;4981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3811463</ArticleId><ArticleId IdType="pubmed">23896472</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kuppeveld F.J., Galama J.M., Zoll J., Melchers W.J. Genetic analysis of a hydrophobic domain of coxsackie B3 virus protein 2B: a moderate degree of hydrophobicity is required for a cis-acting function in viral RNA synthesis. J.&#xa0;Virol. 1995;69:7782&#x2013;7790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189721</ArticleId><ArticleId IdType="pubmed">7494289</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsky R.L., Bauman J.N., Bourcier K., Giddens G., Lapham K., Negahban A., Ryder T.F., Obach R.S., Hyland R., Goosen T.C. Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors. Drug Metab. Dispos. 2012;40:1051&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pubmed">22357286</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., JeBailey L., Ridgway N.D. Oxysterol-binding-protein (OSBP)-related protein 4 binds 25-hydroxycholesterol and interacts with vimentin intermediate filaments. Biochem. J. 2002;361:461&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1222328</ArticleId><ArticleId IdType="pubmed">11802775</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang E.J., Lew K., Casciano C.N., Clement R.P., Johnson W.W. Interaction of common azole antifungals with P glycoprotein. Antimicrob. Agents Chemother. 2002;46:160&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC127000</ArticleId><ArticleId IdType="pubmed">11751127</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Perry J.W., Lauring A.S., Neddermann P., De Francesco R., Tai A.W. Oxysterol-binding protein is a phosphatidylinositol 4-kinase effector required for HCV replication membrane integrity and cholesterol trafficking. Gastroenterology. 2014;146:1373&#x2013;1385, e1&#x2013;e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3992183</ArticleId><ArticleId IdType="pubmed">24512803</ArticleId></ArticleIdList></Reference><Reference><Citation>Warrilow A.G., Parker J.E., Kelly D.E., Kelly S.L. Azole affinity of sterol 14&#x3b1;-demethylase (CYP51) enzymes from Candida albicans and Homo sapiens. Antimicrob. Agents Chemother. 2013;57:1352&#x2013;1360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3591892</ArticleId><ArticleId IdType="pubmed">23274672</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber-Boyvat M., Zhong W., Yan D., Olkkonen V.M. Oxysterol-binding proteins: functions in cell regulation beyond lipid metabolism. Biochem. Pharmacol. 2013;86:89&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">23428468</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong J., Zhang J., Si X., Gao G., Mao I., McManus B.M., Luo H. Autophagosome supports coxsackievirus B3 replication in host cells. J.&#xa0;Virol. 2008;82:9143&#x2013;9153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2546883</ArticleId><ArticleId IdType="pubmed">18596087</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyles J.P., Perry R.J., Ridgway N.D. Characterization of the sterol-binding domain of oxysterol-binding protein (OSBP)-related protein 4 reveals a novel role in vimentin organization. Exp. Cell Res. 2007;313:1426&#x2013;1437.</Citation><ArticleIdList><ArticleId IdType="pubmed">17350617</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J., Dang Y., Ren Y.R., Liu J.O. Cholesterol trafficking is required for mTOR activation in endothelial cells. Proc. Natl. Acad. Sci. USA. 2010;107:4764&#x2013;4769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2842052</ArticleId><ArticleId IdType="pubmed">20176935</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S., Pillai V.C., Mada S.R., Strom S., Venkataramanan R. Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes. Xenobiotica. 2012;42:409&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">22106961</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>